Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy profiles of Watson
Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America
LLC's Elidel® (pimecrolimus) Cream, 1%, and to demonstrate the superior efficacy of the two
active creams over that of the placebo (Vehicle of test product), in the treatment of mild to
moderate atopic dermatitis.